

Plecanatide

Cat. No.:	HY-108741		
CAS No.:	467426-54-6		
Molecular Formula:	C ₆₅ H ₁₀₄ N ₁₈ O ₂₆ S ₄		
Molecular Weight:	1681.89		
Sequence Shortening:	NDECELCVNVACTGCL (Disulfide bridge: Cys4-Cys12; Cys7-Cys15)		
Target:	Guanylate Cyclase		
Pathway:	GPCR/G Protein		
Storage:	Powder	-80°C	2 years
		-20°C	1 year
	In solvent	-80°C	6 months
		-20°C	1 month

BIOLOGICAL ACTIVITY

Description	Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC ₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis ^{[1][2][3]} .										
IC₅₀ & Target	EC ₅₀ : 190 nM (guanylate cyclase-C) ^[1]										
In Vitro	Plecanatide (1 nM-10 μM) activates GC-C receptor to stimulate cyclic guanosine monophosphate (cGMP) synthesis in a dose-dependent manner with EC ₅₀ of 190 nM in T84 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.										
In Vivo	<p>Plecanatide (0.5 and 2.5 mg/kg, p.o.) ameliorates spontaneous and chemically induced colitis after treatment for 7 days in BALB/c mice, and 14 days in TCRα^{-/-} mice^[1].</p> <p>Plecanatide (0.005-5 mg/kg, once daily for 7 days) also shows anti-inflammatory activity in dextran sulfate sodium (DSS) and trinitrobenzene sulfonic (TNBS)-induced colitis in BDF-1 mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female BALB/c mice (2-4 month old) are induced colitis by TNBS^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0, 0.5 and 2.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o. for 7 days</td> </tr> <tr> <td>Result:</td> <td>Effectively reduced colitis severity scores as compared to vehicle treatment.</td> </tr> </table>			Animal Model:	Female BALB/c mice (2-4 month old) are induced colitis by TNBS ^[1]	Dosage:	0, 0.5 and 2.5 mg/kg	Administration:	P.o. for 7 days	Result:	Effectively reduced colitis severity scores as compared to vehicle treatment.
Animal Model:	Female BALB/c mice (2-4 month old) are induced colitis by TNBS ^[1]										
Dosage:	0, 0.5 and 2.5 mg/kg										
Administration:	P.o. for 7 days										
Result:	Effectively reduced colitis severity scores as compared to vehicle treatment.										

REFERENCES

[1]. Shailubhai K, et, al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):213-22.

[2]. Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018 Jun 8;11:1756284818777945.

[3]. Shailubhai K, et, al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe. Dig Dis Sci. 2013 Sep;58(9):2580-6.

Caution: Product has not been fully validated for medical applications. For research use only.

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com Website: www.lifetechindia.com